Anti-CD20 monoclonal antibodies: Beyond B-cells

作者：Avivi Irit^*; Stroopinsky Dina; Katz Tamar

来源：Blood Reviews, 2013, 27(5): 217-223.

DOI：10.1016/j.blre.2013.07.002

• Anti-CD20 monoclonal antibodies (MoAbs)
• Rituximab
• Autoimmune diseases
• Lymphoma
• T-cells
• B-cells

Anti-CD20 monoclonal antibodies (MoAbs), employed in treating CD20(+) lymphomas and autoimmune diseases, appear to have broader functions than just eradicating malignant B-cells and decreasing autoantibody production. Rituximab-induced T-cell inactivation, reported both in-vitro and in-vivo, may contribute to the increased risk of T-cell-dependent infections, observed in patients receiving this therapy. T-cell polarization into a suppressive phenotype, often observed in patients receiving rituximab for autoimmune disorders, was reported to be associated with prolonged remissions. %26lt;br%26gt;Elimination of B-cells serving as antigen-presenting cells, thereby causing impaired T-cell activation, could play a significant role in induction of these changes. Direct binding of rituximab to a CD20(dim) T-cell population, inducing its depletion, may contribute to the decreased T-cell activation following rituximab therapy. %26lt;br%26gt;Further investigation of the complex network through which rituximab and new anti-CD20 MoAbs act, would advance the employment of these agents in different clinical settings.

• 出版日期2013-9